In the news
America's Greatest Disruptors: Mind Blowers
Co-Founder and CTO of Telesis Bio, Dan Gibson was featured as one of America’s Greatest Disruptors by Newsweek magazine. Learn more about Dan and his team of scientists at Telesis Bio and their journey of innovation in synthetic biology.
Converting Digital to Biological: John Gill, Telesis Bio
John Gill, Sr. Director of Research & Innovation at Telesis Bio, discusses the benefits of automated Synthetic Biology to develop new therapeutics and biologics and how the company plays a key role in what has become a dynamic marketplace for DNA.
Telesis Bio Caps off Big Year
It was a year for growth for Telesis Bio. The Telesis Bio team made tremendous strides resulting in a stellar 2022 where they exceeded revenue expectations, delivered meaningful expansion of gross margin due to favorable product mix and cost stabilization and importantly, delivered key products for their customers and achieved milestones for their partners.
The Innovation Awards 2022
It’s time for The Medicine Maker to welcome you to 2022’s most innovative new technologies in drug development and manufacturing – as nominated by the community. Telesis Bio’s BioXp 9600 — the synthetic biology workstation for accelerating synthesis of genes, clones, and variant libraries — was shortlisted in the 2022’s most innovative new technologies in drug development and manufacturing.
Automating DNA Synthesis Boosts Drug Discovery
Current synthetic biology solutions for discovery workflows pose many limitations, whether the workflows are for engineered proteins, therapeutic antibodies, or cell-based immunotherapies. All too often, the turnaround times are too long, especially for complex projects. Fortunately, these difficulties may be addressed by recent advances in automated synthetic biology platforms. Innovative solutions that combine the reliability and speed of automation with industry-leading synthesis chemistry are bringing synthetic biology back into laboratories, enabling rapid overnight synthesis with barely any hands-on time required.
Can A Desktop DNA Printer Stomp Out The Next Pandemic?
Telesis Bio brings the ability to write DNA to every lab with their desktop automated gene synthesis platform, Digital-to-biological converter. Typically, synthesizing DNA starts out with taking four bottles of chemicals, each corresponding to one of the letters of the genetic code and joining them together in a chemical reaction. This time-consuming process was first developed in the 1980s and involves the use of toxic chemicals. One of the things that Telesis Bio is doing is replacing chemical synthesis with faster and more benign enzyme chemistry. They have developed a new DNA synthesis chemistry known as SOLA (short oligonucleotide ligation assembly), which will be integrated into the BioXP™ 9600 system in 2023.
mRNA printers kick-start personalized medicines for all
Most mRNA-based vaccines and therapies still rely on externally sourced plasmid DNA. The BioXp™ system generates multiple oligomers, from which it assembles full-length DNA or mRNA sequences as required. An mRNA printer like the BioXp system could make personalized point-of-care mRNA therapies affordable for more patients around the globe than at present. Although technology has to be realized, a new era of low-cost on-demand clinical-grade RNA is imminent.
Synth revival – In the new world enzymatic DNA synthesis will accelerate drug discovery and development
The recent rise of mRNA-based vaccines and therapies has made gene synthesis even more important in discovery and development pipelines. There’s a new approach to building DNA that uses enzymatic processes rather than chemicals to construct oligos, genes, or even entire genomes. With enzymatic DNA synthesis (EDS), scientists in pharmaceutical and biotech companies can safely bring gene synthesis into their workflows, giving them better control over timelines, costs, and intellectual property.
DNA Synthesis Heads Back to the Bench with New Enzymatic Methods
For years, outsourcing has been standard practice for nearly all DNA synthesis needs. But this arrangement came at a price: long turnaround times that may extend to weeks or months, as well as high costs for higher-quality products. Enzymatic DNA synthesis approaches will finally make it possible to put this capability back in the lab where it belongs, giving researchers control of their DNA products with much faster results. While TdT-based synthesis approaches may require several more years to be commercially attractive, a hybrid method for short oligo ligation and assembly could realize the promise of enzymatic DNA synthesis in the near future.
Enzymatic Approaches Promise To Bring DNA Synthesis Back to Labs
Dan Gibson, CTO of Telesis Bio, shares how enzymatic DNA synthesis (EDS), a new generation of synthesis technologies, promises to deliver in-house synthesis capabilities so scientists can make the yield of DNA required without generating hazardous waste byproducts. With an EDS-based platform in the lab, researchers can build DNA on-demand, rather than having to wait days or weeks for a vendor to manufacture and ship it.
2022 Fast Company’s World Changing Ideas Awards: pandemic response category
We’re honored that our BioXp™ mRNA small-scale synthesis kit was selected as an honoree for the 2022 Fast Company’s World Changing Ideas Awards for the pandemic response category. We couldn’t be prouder for playing a key role in providing the scientific community with the tools needed to fight the pandemic.
Proven mRNA Technologies Embolden Vaccine and Drug Makers
In the vaccine industry, as well as in the broader pharmaceutical industry, expectations for mRNA technology used to be modest. But all that changed with the urgent response to the COVID-19 pandemic. Suddenly, the world witnessed a pair of mRNA breakthroughs. Krishna Kannan, PhD, director of research and development at Telesis Bio asserts that the Telesis Bio BioXp™ system is the first benchtop system for the synthesis of biopolymers. Kannan describes how a Telesis Bio user can print DNA or mRNA for testing vaccines against viruses such as SARS-CoV-2: To start, the customer inputs the desired sequence into the company’s web portal.
Without the ability to synthesize DNA, biotechnology would not be a shred of what it is today. In this episode, Telesis Bio’s Senior Director of Research and Development, Dr. John Gill, talks to us about the future of DNA synthesis technology and how he and those working at Telesis Bio are trying to bring DNA synthesis to the lab bench. This innovative technology will massively increase productivity by reducing the time it takes for DNA to arrive from external producers. The methods used are also non-toxic, providing a better alternative to current DNA synthesis technologies that produce toxic chemicals.
New Technologies for Vaccine Development
The all-encompassing devastation that SARS-CoV-2 has brought to the world has sparked urgency in improving vaccine development as current standards are not always effective and are also time-consuming. Telesis Bio’s BioXp™ system is tackling issues associated with generating vaccines through its automated approach by synthesizing custom DNA overnight, eliminating the need for cells and eggs to incubate the virus, and shortening the virus production process from months to days.
San Diego-Based Company Signs Deal with Pfizer to Speed Up Vaccine Production
A San Diego-based company, Telesis Bio, just signed a licensing deal with Pfizer intended to help speed up the production of vaccines. The company’s CEO, Todd Nelson, gave NBC 7’s Madison Weil a tour of a laboratory on Monday, demonstrating how their unique technology could change the way vaccines are made worldwide.
Todd Nelson, President, and CEO of Telesis Bio was listed on San Diego Business Journal’s SD 500, being named one of the most influential people in health and life sciences in San Diego. Todd joins a list of 500 incredible community business leaders from various industries working towards the city’s economic prosperity.
Telesis Bio buys Eton Bioscience for $13m as San Diego synthetic biology firms join forces
Telesis Bio, fresh off raising $122 million in an initial public stock offering in June, has inked a deal to buy privately held Eton Bioscience — combining two of San Diego’s synthetic biology tools and services companies. Telesis Bio will pay $13 million for Eton, which provides therapeutic discovery services ranging from DNA sequencing to rapid, inexpensive copying of certain biological fragments for research.
How Synthetic Biology Has Shaped COVID-19
Innovations in DNA and RNA synthesis technologies have made a meaningful difference in the battle against COVID-19. Automating steps involved in synthetic biology — including DNA and RNA synthesis — has been essential to how synthetic biology has shaped the COVID-19 response. Enhancing the current automation platforms and continuing to automate manual steps will be crucial for building on the momentum of synthetic biology and expanding its benefits to areas beyond infectious disease such as cancer, metabolic and genetic disorders.
An insect could be the end of citrus in California
Citrus greening is a fatal plant disease that could wipe out an entire industry if left unchecked. In collaboration with the University of Florida, the University of California at Riverside, USDA, Cornell University, and Agrosource, scientists at Telesis Bio will participate in a recently funded grant to tackle this disease. The Telesis Bio team is using the Vmax™ X2 product line for developing a therapeutic molecule discovery platform.
Telesis Bio Releases Full-Length Synthetic Genome for Highly Infectious SARS-CoV-2 Delta Variant
Telesis Bio announced that it released its first full-length synthetic genome for the highly infectious Delta variant of the SARS-CoV-2 virus (B.1.617 lineage). The latest genome for the Delta variant was sequenced using the company’s BioXp™ 3250 system, a fully automated synthetic biology benchtop workstation for rapid, accurate, and reproducible writing of DNA and mRNA.
Seven Up-and-Coming COVID-19 Drugs
Telesis Bio’s recombinant SARS-CoV-2 genomes serve as quality-assured source material used by industry and academic researchers to study mechanisms of viral infection, transmission, and pathogenesis. The company’s BioXp™ and industry-standard Gibson Assembly technologies facilitate rapid de novo synthesis and assembly of emerging variants.
The Future of Synthetic Genomes with Telesis Bio
Telesis Bio’s creation and release of the world’s first full-length synthetic genomes for the three COVID-19 virus variants is a game-changer, not just for the pandemic but for the approach scientists will bring to future health crises. We sat down with Jason Lehmann, product marketing manager for Telesis Bio, to dive into the creation of genomes, how Telesis Bio responded to the pandemic and the future of synthetic DNA.
Co. Releases Full-Length Synthetic Genome of COVID-19 Variants
Telesis Bio released the world’s first full-length synthetic genomes of the SARS-CoV-2 variants to help researchers develop the life-saving therapies and vaccines needed to tackle the coronavirus pandemic. Telesis Bio’s technology saves companies time during the design-build-test phase of their work and streamlines what was once an inefficient process of extracting DNA for analysis.